| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| TuHURA Biosciences Inc. | REM-001 | Cutaneous Metastatic Breast Cancer (CMBC) | Phase 3 | Looking for Funding | Intravenous | Oncology |
| TuHURA Biosciences Inc. | REM-001 | Cutaneous Metastatic Breast Cancer (CMBC) | Phase 3 | Looking for Funding | Intravenous | Oncology |
| TuHURA Biosciences Inc. | Immune Fx (IFx-2.0) | Cancer vaccine for merkel cell carcinoma (MCC) | Phase 3 | Ongoing | Oral | Oncology |
| TuHURA Biosciences Inc. | Immune Fx (IFx-2.0) | Cancer vaccine for merkel cell carcinoma (MCC) | Phase 3 | Ongoing | Oral | Oncology |
| TuHURA Biosciences Inc. | Paxalisib (GDC-0084), VAL-083, Troriluzole, and VT1021 - (GBM AGILE) | Glioblastoma (GBM) | Phase 2/3 | Trial Completed | Oral | Oncology |
| TuHURA Biosciences Inc. | Paxalisib (GDC-0084), VAL-083, Troriluzole, and VT1021 - (GBM AGILE) | Glioblastoma (GBM) | Phase 2/3 | Trial Completed | Oral | Oncology |
| TuHURA Biosciences Inc. | VAL-083 | MGMT-unmethylated Recurrent Bevacizumab Naïve Glioblastoma Multiforme (GBM) or The Adjuvant | Phase 2 | Ongoing | Intravenous | Oncology |
| TuHURA Biosciences Inc. | VAL-083 | MGMT-unmethylated Recurrent Bevacizumab Naïve Glioblastoma Multiforme (GBM) or The Adjuvant | Phase 2 | Ongoing | Intravenous | Oncology |